AstraZeneca PLC (CH:ZEG)
:ZEG
ZEG Stock Chart & Stats
CHF121.57
CHF0.00(0.00%)
At close: 4:00 PM EST
CHF121.57
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF121.57 - CHF151.39
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF233.21B
Enterprise ValueCHF304.39B
Total Cash (Recent Filing)CHF7.67B
Total Debt (Recent Filing)CHF33.92B
Price to Earnings (P/E)27.5
Beta0.11
Next Earnings
Jul 27, 2026EPS Estimate
1.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.74
Shares Outstanding1,551,009,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF172.68Price Target Upside42.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)0.11
Revenue Forecast (FY)CHF675.88M
Bulls Say, Bears Say
Bulls Say
High And Improving ProfitabilityMulti-year revenue expansion to ~60.8B TTM combined with very high gross margins and improved operating/net margins supports durable cash generation. Strong margins underpin sustainable investment in R&D, manufacturing and shareholder returns over the next 2–6 months and beyond.
Robust Pipeline And Consistent R&D DeliveryMultiple successful Phase III readouts and rising trial activity materially de-risk future launches and broaden late-stage optionality. Persistent R&D execution and platform investments increase probability of durable new product flows that can sustain mid-term revenue and margin expansion.
Leading Oncology Franchises Driving GrowthA diversified, high-growth oncology portfolio provides a stable, high-margin revenue base. Large, growing brands and alliance-derived sales (e.g., Enhertu) create durable cash flows, support scale advantages in launches and manufacturing, and reduce dependency on any single product.
Bears Say
Sizeable Total Debt BurdenAlthough leverage has improved, a large absolute debt stock constrains financial flexibility. Elevated debt increases sensitivity to rising finance costs and limits bandwidth for big M&A or opportunistic spend, making capital allocation more constrained over the medium term.
Rising Near-term Cash Outflows And Investment NeedsMaterial increases in CapEx, higher R&D intensity and large milestone payments will pressure free cash flow conversion in the coming quarters. That reduces surplus cash for buybacks or debt paydown and raises reliance on operating performance to fund strategic priorities.
Regulatory And Clinical Outcome UncertaintyAdvisory-panel setbacks and mixed trial readouts introduce approval and timing risk for late-stage assets. Delays or additional data requirements can push expected revenues out, increase development costs, and temper near-term pipeline contribution despite strong earlier readouts.
AstraZeneca News
ZEG FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest stock price was CHF121.57 and its highest was CHF151.38 in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is CHF233.21B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Jul 27, 2026 which is in 30 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Apr 29, 2026. The company reported CHF2.051 earnings per share for the quarter, beating the consensus estimate of CHF2.003 by CHF0.048.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC does not currently pay dividends.
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 1.98.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,551,009,800 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of CHF2.051 in its last earnings report, beating expectations of CHF2.003. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in CH:ZEG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF172.68 (42.04% Upside)
CHF172.68 (42.04% Upside)
Blogger Sentiment
Bullish
CH:ZEG Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF1.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.70%
12-Months-Change
Fundamentals
Return on Equity
22.41%
Trailing 12-Months
Asset Growth
5.03%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
ZEG Stock 12 Month Forecast
Average Price Target
CHF172.68
▲(42.04% Upside)
Technical Analysis
ConvaTec
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---